Skip Nav Destination
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Issue Archive
September 3 2009
Table of Contents
INSIDE BLOOD
BLOOD WORK
REVIEW ARTICLES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families
Clinical Trials & Observations
Willem M. Lijfering,Nic J. G. M. Veeger,Saskia Middeldorp,Karly Hamulyák,Martin H. Prins,Harry R. Büller,Jan van der Meer
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Clinical Trials & Observations
Elias Jabbour,Daniel Jones,Hagop M. Kantarjian,Susan O'Brien,Constantine Tam,Charles Koller,Jan A. Burger,Gautam Borthakur,William G. Wierda,Jorge Cortes
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience
Clinical Trials & Observations
Pau Abrisqueta,Arturo Pereira,Ciril Rozman,Marta Aymerich,Eva Giné,Carol Moreno,Ana Muntañola,María Rozman,Neus Villamor,Kate Hodgson,Elías Campo,Francesc Bosch,Emili Montserrat
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Clinical Trials & Observations
Cindy L. Schwartz,Louis S. Constine,Doojduen Villaluna,Wendy B. London,Robert E. Hutchison,Richard Sposto,Steven E. Lipshultz,Charles S. Turner,Pedro A. deAlarcon,Allen Chauvenet
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
Clinical Trials & Observations
Alexander Claviez,Carme Canals,Daan Dierickx,Jerry Stein,Isabel Badell,Andrea Pession,Stephen Mackinnon,Shimon Slavin,Jean-Hugues Dalle,Manuel Jurado Chacón,Mahmoud Sarhan,Robert Francis Wynn,Meinolf Suttorp,Giorgio Dini,Anna Sureda,Norbert Schmitz,on behalf of the Lymphoma and Pediatric Diseases Working Parties
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Clinical Trials & Observations
Twyla B. Bartel,Jeff Haessler,Tracy L. Y. Brown,John D. Shaughnessy, Jr,Frits van Rhee,Elias Anaissie,Terri Alpe,Edgardo Angtuaco,Ronald Walker,Joshua Epstein,John Crowley,Bart Barlogie
GENE THERAPY
AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells
Federico Mingozzi,Janneke J. Meulenberg,Daniel J. Hui,Etiena Basner-Tschakarjan,Nicole C. Hasbrouck,Shyrie A. Edmonson,Natalie A. Hutnick,Michael R. Betts,John J. Kastelein,Erik S. Stroes,Katherine A. High
HEMATOPOIESIS AND STEM CELLS
Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation
Anna Rita Migliaccio,Fabrizio Martelli,Maria Verrucci,Massimo Sanchez,Mauro Valeri,Giovanni Migliaccio,Alessandro Maria Vannucchi,Maria Zingariello,Angela Di Baldassarre,Barbara Ghinassi,Rosa Alba Rana,Yvette van Hensbergen,Willem E. Fibbe
IMMUNOBIOLOGY
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity
Susanne Wilde,Daniel Sommermeyer,Bernhard Frankenberger,Matthias Schiemann,Slavoljub Milosevic,Stefani Spranger,Heike Pohla,Wolfgang Uckert,Dirk H. Busch,Dolores J. Schendel
LYMPHOID NEOPLASIA
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)
Ilaria Iacobucci,Clelia Tiziana Storlazzi,Daniela Cilloni,Annalisa Lonetti,Emanuela Ottaviani,Simona Soverini,Annalisa Astolfi,Sabina Chiaretti,Antonella Vitale,Francesca Messa,Luciana Impera,Carmen Baldazzi,Pietro D'Addabbo,Cristina Papayannidis,Angelo Lonoce,Sabrina Colarossi,Marco Vignetti,Pier Paolo Piccaluga,Stefania Paolini,Domenico Russo,Fabrizio Pane,Giuseppe Saglio,Michele Baccarani,Robin Foà,Giovanni Martinelli
MYELOID NEOPLASIA
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Brief Report
Simona Soverini,Alessandra Gnani,Sabrina Colarossi,Fausto Castagnetti,Elisabetta Abruzzese,Stefania Paolini,Serena Merante,Ester Orlandi,Silvia de Matteis,Antonella Gozzini,Ilaria Iacobucci,Francesca Palandri,Gabriele Gugliotta,Cristina Papayannidis,Angela Poerio,Marilina Amabile,Daniela Cilloni,Gianantonio Rosti,Michele Baccarani,Giovanni Martinelli
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
VASCULAR BIOLOGY
-
Cover Image
Cover Image
![issue cover]()
A highly F18-FDG-avid focal myeloma lesion (top image) resolved on follow-up PET-CT examination after 2 cycles of induction therapy (bottom image). When systematically examined as part of Total Therapy 3, such PET-CR status achieved prior to first transplantation was a prognostic indicator of reduced risk of relapse by 49% and of death by 59%, independent of risk as defined by gene array analysis. See the article by Bartel et al on page 2068.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
